J&J says its Covid vaccine boost shot has generated a promising immune response in early trials

A man receives a Johnson & Johnson Covid-19 vaccine shot at a pop-up vaccination center on the beach, in South Beach, Florida, on May 9, 2021.

Eva Marie Uzcategui | AFP | Getty Images

Johnson & Johnson said Wednesday that a surge in reinforcement of its Covid-19 vaccine has generated a promising immune response in early clinical trials in its early stages – although information provided by the company in a press release was read on some details.

The J&J vaccine requires only one dose and recipients are considered completely vaccinated two weeks after receiving the shot. The company said Wednesday that J&J recipients who received a booster dose had generated anti-virus antibodies “nine times higher” than those seen four weeks after a single dose.

Increased antibody responses were observed in participants in vaccination trials between the ages of 18 and 55 years, the company said, and in those 65 years and older who received a lower dose of the booster shot. .

The results are based on two Phase 1/2 studies, according to the company.

“We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent for eight months,” said in a statement Dr. Mathai Mammen, head of research and development at the vaccine arm. Janssen says J & J..

“With these new data, we also see that a booster dose of Johnson & Johnson COVID-19 vaccine also increases antibody responses among study participants who had previously received our vaccine,” he added.

While the new data is promising, the company’s press release made no mention of the potential recovery impacts on the delta variant or on safety.

When asked about the delta data, J&J told CNBC in a July report that showing a single dose of the vaccine generated a promising immune response to the variant.

It also raises questions about why J&J recipients need reinforcement shots – especially after the July report showed that a single shot of their vaccine provides immunity that lasts at least eight months and appears to provide adequate protection against the variant. delta to rapid diffusion.

To be sure, the Centers for Disease Control and Prevention said J&J recipients will likely need a dose of reinforcement, but added that they don’t have enough data now to support a formal recommendation.

The company said Wednesday it is engaging with the Food and Drug Administration and other health authorities regarding reinforcements.

J&J did not immediately respond to additional questions from CNBC on these issues.

The new data comes less than a week after J&J announced that Alex Gorsky was stepping down as CEO. Gorsky, 61, who was president and CEO for nine years, will become executive chairman.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button